CN108513574B - N-磺酰化吡唑并[3，4-b]吡啶-6-甲酰胺和使用方法 - Google Patents

N-磺酰化吡唑并[3，4-b]吡啶-6-甲酰胺和使用方法 Download PDF

Info

Publication number
CN108513574B
CN108513574B CN201680069459.4A CN201680069459A CN108513574B CN 108513574 B CN108513574 B CN 108513574B CN 201680069459 A CN201680069459 A CN 201680069459A CN 108513574 B CN108513574 B CN 108513574B
Authority
CN
China
Prior art keywords
pyridine
carboxamide
pyrazolo
phenyl
cyclobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680069459.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN108513574A (zh
Inventor
R.阿卡里
L.J.阿尔维
X.M.波克
B.S.布朗
P.I.R.克莱斯
M.D.科瓦特
E.德勒莫斯
N.德斯罗伊
B.杜蒂安
G.A.格菲泽尔
R.L.M.戈斯米尼
C.G.霍斯曼
K.K.詹森
纪建国
P.R.凯姆
J-M.勒弗朗索瓦
O.马莫利蒂
C.J.M.梅内特
N.M.梅拉尤
G.J.R.纽索姆
A.M.E.帕利斯
S.V.帕特尔
M.R.皮佐内罗
A.什雷斯塔
E.C.斯威夫特
S.E.范德普拉斯
王学庆
A.德布利克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
AbbVie Inc
Original Assignee
Galapagos NV
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV, AbbVie Inc filed Critical Galapagos NV
Publication of CN108513574A publication Critical patent/CN108513574A/zh
Application granted granted Critical
Publication of CN108513574B publication Critical patent/CN108513574B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201680069459.4A 2015-10-09 2016-10-07 N-磺酰化吡唑并[3，4-b]吡啶-6-甲酰胺和使用方法 Active CN108513574B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562239647P 2015-10-09 2015-10-09
US62/239647 2015-10-09
US201662309794P 2016-03-17 2016-03-17
US62/309794 2016-03-17
PCT/IB2016/056029 WO2017060874A1 (en) 2015-10-09 2016-10-07 N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use

Publications (2)

Publication Number Publication Date
CN108513574A CN108513574A (zh) 2018-09-07
CN108513574B true CN108513574B (zh) 2021-01-05

Family

ID=57209654

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680069459.4A Active CN108513574B (zh) 2015-10-09 2016-10-07 N-磺酰化吡唑并[3，4-b]吡啶-6-甲酰胺和使用方法

Country Status (32)

Country Link
US (4) US9890158B2 (enExample)
EP (1) EP3359541B1 (enExample)
JP (1) JP6779992B2 (enExample)
KR (1) KR20180083323A (enExample)
CN (1) CN108513574B (enExample)
AU (1) AU2016333856C1 (enExample)
BR (1) BR112018007161B1 (enExample)
CA (1) CA3001096A1 (enExample)
CL (1) CL2018000911A1 (enExample)
CO (1) CO2018003716A2 (enExample)
CR (1) CR20180215A (enExample)
CY (1) CY1123545T1 (enExample)
DK (1) DK3359541T3 (enExample)
EC (1) ECSP18032223A (enExample)
ES (1) ES2829636T3 (enExample)
HR (1) HRP20201618T1 (enExample)
HU (1) HUE051067T2 (enExample)
IL (1) IL258553A (enExample)
LT (1) LT3359541T (enExample)
MX (1) MX379276B (enExample)
NZ (1) NZ741223A (enExample)
PE (1) PE20181348A1 (enExample)
PH (1) PH12018500765B1 (enExample)
PL (1) PL3359541T3 (enExample)
PT (1) PT3359541T (enExample)
RU (1) RU2724345C2 (enExample)
SG (1) SG11201802932VA (enExample)
SI (1) SI3359541T1 (enExample)
TW (1) TWI720032B (enExample)
UY (1) UY36943A (enExample)
WO (1) WO2017060874A1 (enExample)
ZA (1) ZA201802976B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3183254T (pt) 2014-08-21 2019-08-29 Boehringer Ingelheim Int Novos compostos de espiro[3h-indole-3,2¿-pirrolidin]-2(1h)-ona e derivados como inibidores de mdm2-p53
TWI737635B (zh) 2015-10-09 2021-09-01 德商百靈佳殷格翰國際股份有限公司 作為mdm2－p53抑制劑之新穎螺﹝3h－吲哚－3，2´－吡咯啶﹞－2（1h）－酮化合物及其衍生物
SI3359541T1 (sl) 2015-10-09 2021-01-29 Abbvie Overseas S.A R.L. N-sulfonirani pirazolo(3,4 b)piridin-6-karboksamidi in postopki uporabe
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
EP3558982A1 (en) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
GB201905711D0 (en) * 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US20220267300A1 (en) * 2019-06-12 2022-08-25 NodThera Limited Sulfonamide derivatives and uses thereof
US11236067B2 (en) 2019-07-12 2022-02-01 Orphomed, Inc. Compound for treating cystic fibrosis
CN114206892A (zh) * 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (2-乙酰氨基)硫代-β-D-吡喃半乳糖苷衍生物
KR102836833B1 (ko) * 2019-12-10 2025-07-22 에프. 호프만-라 로슈 아게 신규 메틸퀴나졸리논 유도체
WO2021242505A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
MX2022015495A (es) 2020-06-08 2023-03-14 Halia Therapeutics Inc Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7).
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP4199914A4 (en) 2020-08-20 2024-09-04 The Board of Trustees of the Leland Stanford Junior University METHODS OF TREATMENT OF RESPIRATORY DISEASES CHARACTERIZED BY HYPERSECRETION OF MUCUS
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022150174A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2022150173A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
IL314449A (en) 2022-02-03 2024-09-01 Vertex Pharma Methods of treatment for cystic fibrosis
IL314691A (en) 2022-02-03 2024-10-01 Vertex Pharma PREPARATION METHODS AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.112.3.1. NONADECA-1(18),2,4,14,16-PENTAEN-6-OL
CA3251045A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR IN CYSTIC FIBROSIS
US20250332151A1 (en) 2022-05-16 2025-10-30 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN115806532A (zh) * 2022-08-31 2023-03-17 大连百傲化学股份有限公司 一种mit中杂质的制备方法
WO2024059200A1 (en) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors
CN115960100B (zh) * 2022-12-28 2023-08-18 北京康立生医药技术开发有限公司 一种治疗胃肠道间质瘤药物皮咪特昔布的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014081820A1 (en) * 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small molecule cftr correctors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
CA2559629A1 (en) * 2004-03-16 2005-09-29 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
PT1773816E (pt) 2004-06-24 2015-04-29 Vertex Pharma Moduladores de transportadores de cassete de ligação de atp
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
WO2006004188A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrazolopyridine derivatives
US8362031B2 (en) * 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
CN101687883B (zh) 2007-05-25 2012-05-23 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
JP2011503103A (ja) * 2007-11-07 2011-01-27 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド タンパク質輸送の調節方法
CN101939054B (zh) 2007-12-10 2014-10-29 诺华股份有限公司 有机化合物
WO2009076593A1 (en) 2007-12-13 2009-06-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
RU2518479C2 (ru) 2008-10-23 2014-06-10 Вертекс Фармасьютикалз Инкорпорейтед Твердые формы n-(7-азабицикло[2.2.1]гептан-7-ил-)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида
WO2010078103A1 (en) 2008-12-30 2010-07-08 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
PT2616444E (pt) * 2010-09-14 2015-12-09 Inst Biochemii I Biofizyki Pan Compostos como moduladores de uma proteína cftr mutante e seu uso para tratar doenças associadas à disfunção da proteína cftr
PL2624695T3 (pl) 2010-10-08 2016-03-31 Nivalis Therapeutics Inc Nowe podstawione związki chinolinowe jako inhibitory reduktazy S-nitrozoglutationu
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
AU2012312520A1 (en) 2011-09-20 2014-05-08 The University Of North Carolina At Chapel Hill Regulation of sodium channels by PLUNC proteins
CA2853439A1 (en) * 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
LU92578B1 (fr) 2013-05-07 2014-12-15 Galapagos Nv Nouveaux composés et compostions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose
PE20160286A1 (es) 2013-08-08 2016-05-22 Galapagos Nv DERIVADOS DE TIENO [2,3-c] PIRANO Y SUS COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE LA FIBROSIS QUISTICA
KR20160118345A (ko) * 2014-02-06 2016-10-11 애브비 인코포레이티드 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도
EP3116870A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015138909A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
SG10201803472QA (en) 2014-10-31 2018-06-28 Abbvie Sarl Substituted chromanes and method of use
AU2015339196A1 (en) 2014-10-31 2017-05-11 Abbvie S.A.R.L. Substituted tetrahydropyrans and method of use
BR112018007165A2 (pt) * 2015-10-09 2019-01-22 AbbVie S.à.r.l. novos compostos para tratamento da fibrose cística
SI3359541T1 (sl) * 2015-10-09 2021-01-29 Abbvie Overseas S.A R.L. N-sulfonirani pirazolo(3,4 b)piridin-6-karboksamidi in postopki uporabe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014081820A1 (en) * 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small molecule cftr correctors

Also Published As

Publication number Publication date
KR20180083323A (ko) 2018-07-20
US10647717B2 (en) 2020-05-12
SI3359541T1 (sl) 2021-01-29
CA3001096A1 (en) 2017-04-13
BR112018007161A2 (pt) 2018-10-30
PE20181348A1 (es) 2018-08-22
WO2017060874A1 (en) 2017-04-13
AU2016333856B2 (en) 2021-05-20
PH12018500765A1 (en) 2018-10-01
ES2829636T3 (es) 2021-06-01
US10259810B2 (en) 2019-04-16
TW201722948A (zh) 2017-07-01
HRP20201618T1 (hr) 2020-12-25
LT3359541T (lt) 2020-11-25
US9890158B2 (en) 2018-02-13
US20170101405A1 (en) 2017-04-13
MX2018004359A (es) 2018-05-01
US20190330207A1 (en) 2019-10-31
EP3359541A1 (en) 2018-08-15
CY1123545T1 (el) 2022-03-24
CL2018000911A1 (es) 2018-08-24
DK3359541T3 (da) 2020-11-09
RU2018115722A3 (enExample) 2020-02-18
SG11201802932VA (en) 2018-05-30
RU2724345C2 (ru) 2020-06-23
PT3359541T (pt) 2020-11-11
BR112018007161B1 (pt) 2024-01-16
ECSP18032223A (es) 2018-05-31
AU2016333856C1 (en) 2021-12-09
CR20180215A (es) 2018-06-05
PL3359541T3 (pl) 2021-01-11
UY36943A (es) 2017-05-31
CN108513574A (zh) 2018-09-07
EP3359541B1 (en) 2020-08-05
PH12018500765B1 (en) 2020-11-25
TWI720032B (zh) 2021-03-01
US20180105522A1 (en) 2018-04-19
JP6779992B2 (ja) 2020-11-04
RU2018115722A (ru) 2019-11-12
MX379276B (es) 2025-03-10
NZ741223A (en) 2023-03-31
CO2018003716A2 (es) 2018-07-19
JP2018529743A (ja) 2018-10-11
ZA201802976B (en) 2019-07-31
HUE051067T2 (hu) 2021-01-28
AU2016333856A1 (en) 2018-04-26
IL258553A (en) 2018-05-31
US20190202823A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
CN108513574B (zh) N-磺酰化吡唑并[3，4-b]吡啶-6-甲酰胺和使用方法
CN108431002A (zh) 取代的吡唑并[3，4-b]吡啶-6-甲酸及其用途
CN109970743B (zh) 为jak抑制剂的5-氯-2-二氟甲氧基苯基吡唑并嘧啶化合物
CN103987707B (zh) 吡唑‑4‑基‑杂环基‑甲酰胺化合物以及使用方法
US10450273B2 (en) N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
CN114907338B (zh) 含氮多环稠环类化合物，其药物组合物、制备方法和用途
KR20230173234A (ko) 인다졸계 화합물 및 관련된 사용 방법
CN107428750A (zh) 三唑并吡啶化合物及其使用方法
HK40010369A (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
HK40010369B (zh) 为jak抑制剂的5-氯-2-二氟甲氧基苯基吡唑并嘧啶化合物
HK1245783A1 (en) Triazolopyridine compounds and methods of use thereof
HK1233621A1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
HK40012363A (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
HK1259623A1 (zh) 作爲irak4调节剂的吡唑并[1,5a]嘧啶衍生物
HK1259623B (zh) 作爲irak4调节剂的吡唑并[1,5a]嘧啶衍生物
HK1191938A1 (en) Indazolyl triazole derivatives as irak inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant